other · for chronic fatigue
NMN
Raises NAD, which your cells need to make energy.
Say that in clinical terms
NAD+ precursor restores mitochondrial function, enhances cellular energy production, supports sirtuin-mediated longevity pathways.
How strong is the research?
Solid evidence
Only one studyStudied in a narrower group
1 paper read, 1 supporting.
Who was studied: 13 postmenopausal women who were overweight and prediabetic. A narrow group.
How much to take
daily
250–500 mg
Take in morning for best circadian alignment.
Before you take it
- No NIH ODS Tolerable Upper Intake Level (UL) established for NMN; NIH ODS has no dedicated NMN fact sheet. Human trials have administered up to 1,250 mg/day for 4 weeks and 900 mg/day for 12 weeks without serious adverse events reported, but long-term safety data beyond 12–24 weeks are lacking.
- NMN is structurally distinct from nicotiamide (niacinamide) and nicotinic acid; the IOM/NIH UL of 35 mg/day for nicotinic acid (niacin flush form) does not apply to NMN. NMN does not bind GPR109A and does not cause flushing at typical doses.
- Preclinical signals (mouse studies including a 2025 AACR abstract) indicate elevated NAD+ may support proliferation in some cancer types (e.g., UV-induced skin cancer model); this has not been demonstrated in human trials to date, but the signal warrants caution in individuals with active or recent malignancy pending human data.
- No safety data in pregnancy or lactation; NMN should be avoided in these populations until reproductive safety studies are available.
- No published drug interaction studies exist for NMN; interactions with medications are unknown.
- Multiple senior NMN researchers hold patents or patent-licensing agreements with commercial NMN manufacturers (MetroBiotech USA, Teijin Japan), creating systemic conflict-of-interest across much of the published human trial literature.
What we make of it
A real trial, but it measured insulin sensitivity in muscle, not fatigue.
The detail
The study is genuine — 10 weeks, 25 people — but what it measured was how well muscle responded to insulin. Fatigue was not an outcome, so citing it here misuses it.